+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain Publishes Viral Clearance Market Report 2021-2031

18 February 2021

Visiongain has published a new report on Viral Clearance Market Report 2021-2031: Forecasts by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nano filtration), Viral Inactivation (Low pH)). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Viral Clearance market was valued at US$ xx billion in 2019 and is projected to reach at a market value of US$ xx billion by 2031.

A viral clearance is defined as the removal of viral contamination using specializes membranes or chromatography. In order to ensure that therapeutic drugs derived from certain sources are fully rid of any viral contamination, these protein solutions undergo viral clearance to inactivate or remove viral materials.

COVID-19 Impact on Viral Clearance Market
In this period of pandemic COVID 19. This market is growing in a great speed because this viral clearance shows that the virus is in body or not. Every patient is going through this process.so the demand of this market is increasing in great speed.

Market Drivers
The factors that drive the growth of this market include the strong pharmaceutical product pipeline that will benefit in the development of the pharmaceutical and biotechnical industry, the rising government funding for the pharmaceutical and biotechnology industries, the innovations of novel drug and rise in R&D activities.

There are also factors that hamper the growth of the market like the high degree of consolidation act

Market Opportunities
Virus elimination continue to emerge as an important factor in overall bioprocess safety. As bioprocesses, products, and unit operations flourish, viral clearance will become more customised to industrial and individual situations. At the same time, the global viral clearance market will keep extending in purview.

Regional Analysis
The North American region is expected to record the largest share of the market in 2018. The viral clearance market in the region is driven by the existence of national institutes supporting biotechnology and life science research, progression in the pharmaceuticals industry, and the increasing number of drug approvals. The rising pervasiveness of diseases, growing production of monoclonal antibodies, and government support for the development of drugs are some of the key factors driving the viral clearance market in the US. In Canada, increasing pharmaceutical production is expected to boost the growth of the viral clearance market.

On the other hand, Asia Pacific is expected to witness the highest growth during the analysis period, owing to increase in generics development and manufacturing, surge in funding for medical research and the presence of a large number of CROs to provide preclinical and clinical research services in China, government inventiveness to increase the use of generic drugs, growing aging population in Japan, rise in pharmaceutical R&D expenditures in India, and the growing pharmaceutical manufacturing in Singapore and Malaysia.

Competitive Landscape
Global Viral Clearance market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others to increase their imprints in this market.

Some of the companies mentioned- Wuxi Biologics (Cayman), Merck KgaA (Germany), Charles River Laboratories International Inc (US), Texcell Inc. (France),Kedrion (Italy),Vironova biosafety (Sweden), Clean cells (France), BSL (Bio-service scientific laboratories) Munich GmbH (Germany),Virusure Gmbh(Austria).

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024


Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024


Visiongain Publishes Female Health Tech Market Report 2024-2034

The global Female Health Tech market was estimated to be valued at US$ 140.9 billion in 2034 and is expected to register a CAGR of 9.6% from 2024 to 2034.

05 April 2024


Visiongain Publishes Meningococcal Vaccines Market Report 2024-2034

The global Meningococcal Vaccines market is projected to grow at a CAGR of 2.5% by 2034

26 March 2024